Prix Galien USA Award Nominees Include Clinical Trials Industry Providers
Award candidates and winners to be presented on October 26, 2023, at the Prix Galien USA Forum in NYC.
The Galien Foundation announced the 2023 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," and "Incubators, Accelerators and Equity." And, in partnership with Business France, nominees have also been announced for "Best Startup." Winners will be announced during the Prix Galien USA Forum on October 26, 2023, at the Alexandria Center for Life Science in New York City. Category winners will be announced during the Prix Galien USA Awards Ceremony at the American Museum of Natural History in New York City.
"The Prix Galien Awards Committee is delighted to celebrate this remarkable group of candidates and selecting this year's winners will be no easy feat," said Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth, Prix Galien Medical Technology, Startup, Digital Health and Incubators, Accelerators and Equity Committee Chairman. "This great list of nominees reflects the undeniable courage, dedication, and passion behind each researcher continually working to deliver answers to patients around the world. We applaud their efforts and look forward to celebrating our shared goal of improving the human condition".
Specifically, in the Digital Health Solution category, nominees from the clinical trials sector include: Empatica, Medable, Science 37, uMotif and Viz.AI. The full list of nominees is below.
"I'm honored to be returning as an Awards juror as we commend the unwavering commitment of each winner and award nominee in their perseverance of the advancement of global science, healthcare, and wellness," said Alex Gorsky, Former CEO and Executive Chairman, Johnson & Johnson, member of the Prix Galien Startup, Digital Health and Incubators, Accelerators and Equity Committee. "The outstanding quality of the submissions is a testament to the promising future of the life sciences industries."
Best Digital Health Solution (Nominees)
Reference: The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup". NEW YORK, July 27, 2023 /PRNewswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
